therapeutic areas

Rare and orphan diseases: hemophilia, hereditary angioedema, Fabry, Gaucher, CLL, pulmonary hypertension, hereditary hyper-cholesterolemia, multiple scleroses, Pompe, etc.
Oncology products (traditional and biologic)
Rheumatoid arthritis, Lupus, Psoriatic arthritis (traditional and biologic)
Anti-infective/Anti-viral agents (Anthelmintics, Antibacterial agents, Antibiotics, Antimicotics, HIV, etc.)
Immunosuppressive agents
Antidiabetic agents (oral, injectables, insulins, full coverage)
Antihistamines
Anticoagulants, platelet aggregation inhibitors, thrombolytic agents, etc.
Vaccines
Nuclear medicine
Contraceptives (Contraceptives, intracervical devices, intrauterine devices, intravaginal, sub-dermal implant)
Bronchodilators
Bone diseases (osteoporoses, etc.)
Cardiovascular drugs (Angiotensin converting enzyme inhibitors, Calcium antagonists, Hypotensive agents, Vasodilating agents, etc)
Central nervous system drugs (Analgesics, Anticonvulsants, Antidepressants, Central nervous system depressants, Anxiolytics, Antimanic agents, Alzheimer products, Multiple scleroses, etc.)
Corticoids
Dermatology products, psoriasis
Gastrointestinal drugs (Antacids, Antidiarrhea agents, Cathartics and laxatives, Anti-emetics)
Hormones (Androgens, Contraceptives, Estrogens, Estrogens conjugated, Gonadotropins)
Nutrotherapic products
Dietary supplements (adults, pediatrics)
Infant milk formulas
Ophthalmic (monoclonal, etc.)
Pain management
Sexual dysfunction
Vitamins

Situation diagnosis for the Hereditary Angioedema market in Argentina: Incidence, Treatment and Up-take of the new product. Treatment costs. Approval circuit within institutions. Incorporation circuit of new product within PAMI, IOMA and Pre-paid Healthcare System

Exploratory qualitative study, interviewing specialists (allergies and immunology) and auditors within target institutions.

Able to plan actions to access target institutions based on the positioning of the new product according to cost-benefit assessment in crisis prevention.

Situation diagnosis for the Chronic immune deficiency market: patient workload, referral circuit, diagnosis and indications, brand positioning

Exploratory qualitative study, interviewing Hematologists, Immunologists and Neurologists.

Able to identify specific indications treated with gamma globulin by different specialists and patient workloads; competitive capacity of the product within the market.

Identification of business opportunities within the Hemophilia market: market sizing, patient flow and treatment pathway. Coverage and access to treatment.

Qualitative study with quantitative validation, interviewing hematologists – KOL’s, High Prescribers, auditing Doctors. Type A Hemophilia patients and caregivers.

Able to evaluate with precision the sales potential of the product during the different stages of the disease. Also able to size the strategic opportunity for secondary prevention.